Restricted Distribution Should Be Limited To Drugs With Unique Benefit – FDA
Executive Summary
Risk management plans that include restricted distribution components should be limited to products that offer a unique benefit in a specific group of patients, according to FDA
You may also be interested in...
Negative Arcoxia Review May Reflect Increasingly High Hurdle For Me-Toos
The Arthritis Drugs Advisory Committee's negative review of Merck's Arcoxia could be more indicative of the increasingly challenging regulatory environment for "me too" products than concerns over the Vioxx follow-on's safety profile
Arcoxia Needs Further Study In 1,000s Of Patients, Or Discontinuation – Cmte
Merck's COX-2 inhibitor Arcoxia requires significant additional clinical safety and efficacy evaluation prior to approval, members of FDA's Arthritis Drugs Advisory Committee said in recommending against approval of the Vioxx follow-on for treatment of osteoarthritis
Post-Marketing Study Deadlines Urged As House Tackles FDA Safety Effort
FDA should revisit the post-marketing studies that firms have outstanding, eliminate many of them, and set firm deadlines for the remaining trials, academics suggested at a March 22 hearing by the House Energy and Commerce/Oversight and Investigations Subcommittee